Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs iShares 1 3 Year Treasury Bond ETF (SHY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs iShares 1 3 Year Treasury Bond ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $287.76 (market cap $39.89B), while iShares 1 3 Year Treasury Bond ETF trades at $81.84. Which is the better fit depends on your goals.
| ALNY | SHY | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Fixed Income |
52-Week High | $491.22 | $83.18 |
52-Week Low | $278.09 | $81.84 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
SHY trades at $81.88, down 0.04% with a bearish technical signal from moving averages. The ETF shows neutral momentum oscillators and uniform support/resistance at $82. Recent corporate actions include scheduled dividends of $0.24 per share through mid-2026, providing income stability amid flat price movement.
Outlook remains cautious due to technical bearishness and interest rate sensitivity. Opportunities include consistent dividend yields, while risks involve Federal Reserve policy shifts impacting bond ETFs. Investors should weigh income benefits against potential rate hike volatility in the fixed income sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About iShares 1 3 Year Treasury Bond ETF
SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →
